$522 Mln
$-75 Mln
--
As on 28-Sep-2023 16:00 EDT
$-0.01
•
-1.10%
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Amarin (AMRN)
| -24.80 | -14.16 | -21.56 | -19.48 | -37.96 | -41.97 | -17.91 |
|
S&P BSE Sensex*
| 8.20 | 1.28 | 2.99 | 16.31 | 20.12 | 12.69 | 12.81 |
|
#
| -- | -- | -- | -- | -- | -- | -- |
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|
|---|---|---|---|---|---|---|---|
|
Amarin (AMRN)
| -64.09 | -31.08 | -77.19 | 57.53 | 237.15 | 30.19 | 62.96 |
|
S&P BSE Sensex
| 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 | 1.95 |
|
S&P BSE Sensex
| 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 | 1.95 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
The total asset value of Amarin Corporation plc (AMRN) stood at $ 1,104 Mln as on 31-Mar-23
The share price of Amarin Corporation plc (AMRN) is $0.909900 (NASDAQ) as of 28-Sep-2023 16:00 EDT. Amarin Corporation plc (AMRN) has given a return of -37.96% in the last 3 years.
Amarin Corporation plc (AMRN) has a market capitalisation of $ 522 Mln as on 02-Jun-2023. As per Value Research classification, it is a company.
The P/B ratio of Amarin Corporation plc (AMRN) is 0.80 times as on 02-Jun-2023, a -0.69% premium to its peers’ median range of 2.54 times.
Since, TTM earnings of Amarin Corporation plc (AMRN) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Amarin Corporation plc (AMRN) and enter the required number of quantities and click on buy to purchase the shares of Amarin Corporation plc (AMRN).
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
The CEO & director of Mr. Karim Mikhail. is Amarin Corporation plc (AMRN), and CFO & Sr. VP is Dr. Steven B. Ketchum Ph.D..
The promoters of Amarin Corporation plc (AMRN) have pledged 0% of the total equity as on Dec-22.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
313
|
|
|
286
|
|
|
34
|
|
|
12
|
| Amarin Corporation plc (AMRN) | Ratios |
|---|---|
|
Return on equity(%)
|
-15.47
|
|
Return on capital employed(%)
|
--
|
|
Debt-to-equity ratio
|
0
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Amarin Corporation plc (AMRN) was $-75 Mln.
$521.96 Mln
$360.54 Mln
$-75.10 Mln
$304.37 Mln
$9.84 Mln
High
$0.84 - 2.23
407,780,000
NASDAQ: AMRN
Dublin
https://www.amarincorp.com
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates.... It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland. Read more
Learn the principles, mindset and tools you need to become a successful Mutual Fund and Stock investor from the masters who have been doing this for decades.
Use India's most advanced investment tracker to track, analyse and get updates and insights on your investments.
Get an analysis of your portfolio along with actionable, general tips and insights, guidance on where to invest based on your goals, and experts' opinions on individual Mutual Funds and Stocks.
Value Research offers the most advanced and detailed data & analytics available on Mutual Funds and Stocks. Sign up and unlock the power yourself.
Unlimited access to advice from India's top experts
The most comprehensive analysis of funds and stocks in India
A holistic portfolio manager to help track all your investments easily
And much more, like guides, tools, webinars, videos and eBooks.
Share via Facebook 
Share via Twitter 
Share via LinkedIn 
Share this
